Pharmaceuticals & Therapeutics

enGene hits the road for key investor conferences, showcasing a promising non-viral gene therapy for a tough-to-treat bladder cancer. Will it succeed?

The biotech firm landed $1M at a premium, a sign of investor faith. But with past regulatory hurdles, can this cash pave a new path for its NurOwn® therapy?

Travere Therapeutics reports a profitable Q4 driven by its kidney drug FILSPARI, but a revenue miss and a critical FDA decision create a complex outlook.

A landmark bill to shield living organ donors from job and insurance discrimination is advancing in the Senate, offering new hope for 90,000+ on the waiting list.

INmune Bio will present key Phase III results for CORDStrom, a systemic cell therapy for the devastating rare skin disease RDEB. Will it be a breakthrough?

A renewed deal between Inmar Intelligence and Premier, Inc. highlights the vital, unseen role of reverse logistics in pharmacy finance, compliance, and safety.

A new study reveals a breakthrough hair loss system offers clinically meaningful regrowth for menopausal women in just four months, challenging existing treatments.

In memory of Brynne Coletti, a family's transformational $10M gift will create a new women's cancer program, bringing world-class care to Southwest Florida.

Clene Inc. faces investors with promising data for ALS and MS, but a looming cash crunch makes its upcoming conference a critical test of survival.

New five-year data for SYFOVRE shows a significant delay in geographic atrophy progression, offering long-term hope but also sparking clinical debate.

With a major €12.5M EU funding package, Step Pharma is fast-tracking dencatistat, a novel therapy targeting a key vulnerability in ovarian and endometrial cancers.

With a pivotal data release on the horizon, Passage Bio heads to two major conferences. Can its dementia gene therapy program win over Wall Street?

Milliken's Borchers brand targets Asia's booming coatings market with tailored, eco-friendly additives and expanded technical support from its Pune hub.

Serina Therapeutics enrolls the first patient in a trial for SER-252, a novel Parkinson's therapy designed to improve symptoms without current side effects.

A landmark deal will deploy advanced Belgian particle accelerators across India, aiming to revolutionize cancer diagnostics and patient access in a booming market.

With its CEO and CFO set for key conferences, Aptar will address investors following a strong sales quarter but facing questions on profitability.

With impressive preliminary sales and key pipeline updates, Mirum Pharmaceuticals' upcoming earnings call will focus on its strategy for sustained growth in 2026.

With $3.7M in new capital, Sift Biosciences is developing a novel immunotherapy to awaken the body's memory T cells against hard-to-treat diseases.

The Nashville-based clinic brings its luxury, results-driven skincare model to Arlington, VA, tapping into national wellness trends and rapid growth.

Johnson & Johnson is investing over $1 billion in a new Pennsylvania cell therapy hub, promising revolutionary treatments and thousands of new jobs.